Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 24, 2026Asian Pacific Journal of Cancer PreventionOpen Access

Selective Inhibition of VEGFR2 in Preference to Other Receptor Tyrosine Kinases by Diosgenin, a Natural Steroidal Sapogenin

View Full Paper
Ask AI
Bookmark
Share

Authors

CJCharmi JyotishiMPMansi PatelSPSuresh Prajapati

Discussion

Loading...

Member takes

Overview

Randomized trial assesses diosgenin's selective inhibition of VEGFR2 in the context of angiogenesis, highlighting its therapeutic potential.

Key Points

  • This research evaluates diosgenin's ability to inhibit key receptor tyrosine kinases associated with angiogenesis.
  • Screened 1,525 plant-derived compounds, including 20 sapogenins and 3 diosgenin derivatives for drug-likeness.
  • Docked top candidates against VEGFR2, FGFR1, and PDGFRA using PyRx software.
  • Conducted molecular dynamics simulations to assess protein-ligand complex stability using NAMD3.
  • Diosgenin exhibited the strongest binding to VEGFR2 with a ΔG of -11.03 kcal/mol, outperforming lenvatinib and sorafenib.
  • Complexes involving FGFR1 and PDGFRA showed positive ΔG values, indicating less stable interactions.
  • Three diosgenin derivatives were evaluated, with Formosanin C showing the highest binding among them.

Cite This Study

Jyotishi et al. (2026) studied this question.

synapsesocial.com/papers/6a12959d48a0ea1665671cbfhttps://doi.org/10.31557/apjcp.2026.27.5.1893
View Full Paper
Ask AI
Bookmark
Share